NeoGenomics, Inc. (NASDAQ:NEO) Shares Sold by Glenmede Trust Co. NA

Glenmede Trust Co. NA cut its holdings in shares of NeoGenomics, Inc. (NASDAQ:NEO) by 1.4% in the 3rd quarter, Holdings Channel reports. The firm owned 1,155,439 shares of the medical research company’s stock after selling 16,295 shares during the period. Glenmede Trust Co. NA’s holdings in NeoGenomics were worth $17,043,000 at the end of the most recent reporting period.

Other large investors have also recently added to or reduced their stakes in the company. BNP Paribas Financial Markets lifted its position in shares of NeoGenomics by 110.1% during the 3rd quarter. BNP Paribas Financial Markets now owns 72,963 shares of the medical research company’s stock valued at $1,076,000 after acquiring an additional 38,238 shares during the last quarter. FMR LLC raised its position in shares of NeoGenomics by 7.6% during the third quarter. FMR LLC now owns 13,255 shares of the medical research company’s stock worth $196,000 after purchasing an additional 931 shares during the period. Loomis Sayles & Co. L P purchased a new stake in shares of NeoGenomics during the third quarter valued at $17,807,000. Algert Global LLC boosted its position in shares of NeoGenomics by 204.3% in the 3rd quarter. Algert Global LLC now owns 79,983 shares of the medical research company’s stock valued at $1,180,000 after purchasing an additional 53,700 shares during the period. Finally, Charles Schwab Investment Management Inc. increased its stake in NeoGenomics by 5.4% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 1,134,651 shares of the medical research company’s stock worth $16,736,000 after purchasing an additional 57,677 shares in the last quarter. 98.50% of the stock is currently owned by institutional investors.

NeoGenomics Trading Up 3.3 %

NEO stock opened at $17.74 on Friday. The company has a 50 day moving average of $14.72 and a two-hundred day moving average of $14.89. The company has a current ratio of 1.99, a quick ratio of 1.91 and a debt-to-equity ratio of 0.37. NeoGenomics, Inc. has a 12-month low of $12.77 and a 12-month high of $21.22.

NeoGenomics (NASDAQ:NEO) last released its quarterly earnings data on Tuesday, November 5th. The medical research company reported $0.05 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.01 by $0.04. NeoGenomics had a negative return on equity of 2.11% and a negative net margin of 12.07%. The firm had revenue of $167.80 million during the quarter, compared to analysts’ expectations of $167.00 million. During the same quarter last year, the firm earned ($0.06) earnings per share. The business’s revenue for the quarter was up 10.5% on a year-over-year basis. As a group, research analysts predict that NeoGenomics, Inc. will post -0.17 EPS for the current year.

Insider Activity at NeoGenomics

In other NeoGenomics news, General Counsel Alicia C. Olivo sold 5,175 shares of the stock in a transaction on Friday, November 15th. The shares were sold at an average price of $15.36, for a total transaction of $79,488.00. Following the transaction, the general counsel now directly owns 37,129 shares of the company’s stock, valued at $570,301.44. This represents a 12.23 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Insiders own 1.30% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts have commented on NEO shares. Needham & Company LLC reiterated a “buy” rating and issued a $19.00 target price on shares of NeoGenomics in a report on Wednesday, November 6th. Benchmark reaffirmed a “buy” rating and issued a $18.00 price objective on shares of NeoGenomics in a research note on Tuesday, September 24th. Nine analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company has an average rating of “Buy” and an average price target of $20.25.

About NeoGenomics

NeoGenomics, Inc operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. It operates through Clinical Services and Advanced Diagnostics segments. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories.